Wednesday, October 5, 2016

Thursday, October 6, 2016

Friday, October 7, 2016

  • 8:00 AM - 5:00 PM

    Geneticon Upper Midwest Clinical Genetics

  • 7:00 AM - 8:00 AM

    Continental Breakfast

  • 7:00 AM - 8:00 AM

    Epigenomics and Microbiome Poster Session

    Click here for abstract submission information.

  • 8:00 AM - 12:30 PM

    Workshop Sessions with a Break

  • 8:00 AM - 12:30 PM

    Learn about the TIGER-Bio biomarker development pipeline. Many tumors have multiple mutations, and it is often not clear which mutation or combination of mutations is most critical. TIGER-Bio uses multiple genetic profiling platforms, integrates bioinformatic analysis within and across patient data sets, validates biomarker targets for test development, and uses interpretive tools to synthesize and present complex data into easy to understand reports.

    Targetable treatments – from biomarker discovery to clinical testing Learn about how the TIGER-Bio methodology can discover biomarkers and rapidly develop targetable biological pathways into clinically-available tests.


    • Mitesh Borad, M.D.
    • Mark Truty, MD, MS

    Three-Dimensional Cell Model Systems – individually-derived patient cell models Learn about innovative approaches to derive individual patient tumor cell models to rapidly test potential treatments in vitro.


    • Panagiotis Z. Anastasiadis, Ph.D.
    • 1 other speaker TBD

    From MatePair Sequencing to Integrated Genomics Learn how the foundation of MatePair Sequencing and other innovative approaches can accelerate an integrated genomic evaluation – for biomarker discovery and for potential future individualized patient assessment for treatment.


    • George Vasmatzis, Ph.D.
    • Interactomics: Computational Analysis of Novel Drug Opportunities CANDO
      Ram Samudrala, Ph.D.
  • 8:00 AM - 12:30 PM

    Epigenomics is a rapidly emerging scientific discipline concerned with the global regulation of genome activity including gene transcription, DNA replication and repair. Recent developments in the understanding of epigenetic mechanisms and their role in producing distinct normal and diseased phenotypes, together with advances in epigenomic technology and pharmacology have led to accelerated translation of epigenetic concepts and findings to clinical tests, disease biomarkers and drugs. In this session, leading scientists from diverse backgrounds will discuss how fundamental and clinical research can inform each other in support of creating diagnostic and therapeutic tools of the future.


  • 8:00 AM - 12:30 PM

    Join us for a half-day workshop as we explore the interface between the microbiome and human health. Attendees will obtain state-of-the-art information regarding gut microbial ecology and it relevance in human health with emphasis on functional aspects of the microbiome and their role in causing disease.


  • 8:00 AM - 12:30 PM

    After participating in this workshop, participants will be better equipped to implement pharmacogenomics in a variety of health care settings. They will understand how to use PGx guidelines to facilitate implementation of pharmacogenomics testing.

    Speakers with experience leading the implementation of pharmacogenomics will provide practical guidance on a range of topics, including forming a team, selecting a testing platform, drug/gene selection, informatics, and economic aspects.

    Richard Weinshilboum, M.D. (Modertator)

    7:50AM Introductions & Welcome

    Set the Stage – Background

    8:00AM What genes to implement and how CPIC prioritizes gene/drug
    Kelly E. Caudle, Pharm.D., Ph.D., B.C.P.S.
    8:20AM Testing Options: Pre-emptive vs Reactive
    Stuart Scott, Ph.D.
    8:40AM DPYD Testing: Implementation in Routine Clinical Care
    Jesse Swen, Pharm.D., Ph.D.

    Clinical and Research Application

    9:00AM Education-Clinician and Patient
    Kelly E. Caudle, Pharm.D., Ph.D.
    9:20AM PGx: A Next Step Into the Future
    Prof Magnus Ingelman-Sundberg
    9:55AM Panel Discussion
    Kelly E. Caudle, Pharm.D., Ph.D., Prof Magnus Ingelman-Sundberg, Jesse Swen, Pharm.D., Ph.D. & Stuart Scott, Ph.D.
    10:20AM Break with Refreshments


    10:35AM Organization of a Clinical PGx Service and its Dilemmas
    Vera H.M. Deneer, Pharm.D., M.D.
    10:50AM Hospital-wide Implementation vs. Implementation to Just Specialty Groups
    Peter Hulick, M.D.
    11:05AM Cost/reimbursement
    Stuart Scott, Ph.D.
    11:20AM Cancer PGx Therapy Selection
    Edwin Cuppen, M.D.
    11:35AM Challenges of Implementation in the Digital World
    Robert R. Freimuth, Ph.D.
    11:50AM Panel Discussion
    Edwin Cuppen, M.D., Robert R. Freimuth, Ph.D., Peter Hulick, M.D., Prof Magnus Ingelman-Sundberg, Stuart Scott, Ph.D. & Jesse Swen, Pharm.D., Ph.D.
    Vera H.M. Deneer, Pharm.D., M.D.
    Curated Questions for discussion from the moderator, each speaker answers, as well as questions from the audience
    12:15PM Adjourn